Immunogenicity and Reactogenicity of Vaccine Boosters after ***2.S Priming

作     者：Roos S G Sablerolles 

作者机构：From the Departments of Internal Medicine (R.S.G.S. M.L.) Hospital Pharmacy (R.S.G.S. W.J.R.R. P.H.M.K.) and Viroscience (D.G. K.S.S. M.P.G.K. C.H.G. R.D.V.) and the Department of Internal Medicine Division of Allergy and Clinical Immunology and Department of Immunology (V.A.S.H.D.) Erasmus University Medical Center Rotterdam the Center of Tropical Medicine and Travel Medicine Department of Infectious Diseases (A.G. H.M.G.G.) and the Department of Experimental Immunology Amsterdam University Medical Centers Amsterdam Institute for Infection and Immunity University of Amsterdam (N.A.K.) Amsterdam the Department of Internal Medicine and Infectious Diseases (D.F.P.) and the Department of Medical Microbiology and Infection Prevention University Medical Center Groningen University of Groningen (A.L.W.H. D.B.) Groningen the Department of Infectious Diseases Leiden University Medical Center Leiden (L.G.V.) and the Center for Infectious Disease Control National Institute for Public Health and the Environment Bilthoven (D.B.) — all in the Netherlands.Dr. van der Kuy can be contacted at [email protected] or at the Department of Hospital Pharmacy Erasmus Medical Center Dr. Molewaterplein 40 3015 GD Rotterdam the Netherlands. A full list of the SWITCH Research Group investigators is provided in the Supplementary Appendix available at ***. 

出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)

年 卷 期：2021年第43卷第11期

页      面：1861-1861页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 100705[医学-微生物与生化药学] 1001[医学-基础医学(可授医学、理学学位)] 100103[医学-病原生物学] 10[医学] 

基　　金：ZonMw 

主　　题：vaccine acute respiratory 

摘      要：Background:The ***2.S vaccine,which was approved as a single-shot immunization regimen,has been shown to be effective against severe coronavirus disease ***,this vaccine induces lower severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)spike protein(S)-specific antibody levels than those induced by messenger RNA(mRNA)-based *** immunogenicity and reactogenicity of a homologous or heterologous booster in persons who have received an ***2.S priming dose are unclear.